No company matches — see all tickers
Juan Andres appointed COO to lead manufacturing for a potential intismeran autogene launch and oncology expansion
Zero-interest convertible notes raise funds for potential oncology investment and debt repayment; capped calls aim to limit conversion dilution.
European government COVID deliveries drove H1 growth, while a patent settlement widened losses and drained cash in July.
Norovirus vaccine misses Phase 3 interim early-success criteria, with another cohort planned; cost and R&D outlook lowered.
Former Biogen CFO Michael McDonnell joins the Board and Audit Committee; David Rubenstein moves to Nominating and Corporate Governance.
Coverage: 10-K, 10-Q and 8-K filings filed since Jul 1, 2026.
Request longer coverage
Company data: Wikidata Q17081612
We read every message.
